EDI-200

DB18188InvestigationalProtein Based Therapies

EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member EDAR
Curator reviewed
Also known as: FC:EDA-A1 FUSION PROTEIN · HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN
Code names: APO200 · EDI-200

Resolves to

Targets

Q9UNE0EDAR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with EDI-200, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account